The Texas Therapeutics Institute at The Brown Foundation Institute of Molecular Medicine (TTI-IMM) was established in 2010 with funding from the Texas Emerging Technology Fund, The University of Texas System, and The University of Texas Health Science Center at Houston.
We offer Texas-wide access to specialized technical expertise, instrumentation, and automation to advance lead antibodies with “drug like” properties from academic laboratories to the stage of preclinical development.
Large molecule therapeutics, such as antibodies and other protein-based drugs, has become the major modality of oncology treatments. Discovery and development of drug candidates require detailed characterization of the candidates in pharmacokinetics (PK) and potential toxicity (Tox, also known as safety assessment) in designated animal species, a process called preclinical development. Understanding of PK and Tox is essential for the advancement of the candidates into clinical trials.